Blog / News

May 16, 2022

From 2020-2021, a dramatic increase in the use of illicit fentanyl as well as methamphetamine and cocaine has dramatically contributed to overdose deaths exceeding 100,000. Dr. Bobby Mukkamala, chair of the American Medical Association (AMA), notes addressing current health inequities that might negatively affect minority populations and people of color is especially important as structurally marginalized populations are disproportionately affected by the drug overdose crisis. Current health equity research has addressed the struggles patients from…...... Read More

May 13, 2022

CBAM’s own Dr. Jesse Clark was recently interviewed by NPR about his experience with both the COVID and HIV pandemics and how development of the COVID vaccines have accelerated the pace of development of an HIV vaccine. Click here for the interview feature in its entirety....... Read More

May 3, 2022

Methamphetamine use is a growing global concern that has hampered efforts to address opioid use disorder and HIV infection. Evidence-based behavioral interventions (EBIs) to reduce methamphetamine exist, but current research on optimal EBI combinations to reduce methamphetamine use is limited. In Vietnam, methamphetamine co-use is prevalent in people receiving methadone maintenance treatment (MMT) for opioid use disorder. In response to this co-epidemic, CBAM’s Drs. Michael Li and Steve Shoptaw are collaborating with Dr. Giang Le…...... Read More

April 18, 2022

A NIDA funded analysis of data from the 2018 National Survey of Substance Abuse Treatment Services assessed availability of HIV testing and counseling services in U.S. substance use treatment facilities. Among these facilities, investigators found only three in ten offered HIV testing. Additionally, HIV testing was more likely to be offered in facilities that offered medication for opioid use disorder. Overall, in only three states was HIV testing offered by at least 50% of facilities.…...... Read More

April 13, 2022

HIV diagnosis and prevalence among people who inject drugs has increased alarmingly in recent years. Syringe services programs (SSPs) are both economic and highly effective in reducing HIV transmission and critical to the success of the “Ending the HIV Epidemic” initiative. An in-depth literature review was conducted to assess how critical a role SSPs play in addressing this growing concern. This review concluded SSPs “have the highest impact in HIV prevention when combined with access…...... Read More

April 11, 2022

The Carlat Psychiatry Podcast, a digital program that reviews evidence-based psychiatry, recently provided an overview of the history and pharmacology of methamphetamine use disorder. In this segment, the ADAPT-2 trial published in The New England Journal of Medicine (for which CBAM’s Vine St. Clinic served as a clinical research site and Dr. Shoptaw co-authored) was discussed. To hear the podcast and learn more about the basics of methamphetamine use disorder and the current novel treatment…...... Read More

April 1, 2022

Los Angeles County is launching a guaranteed income project known as “Breathe” to help address financial uncertainty and provide eligible residents with needed monetary assistance. The program will provide 1,000 selected residents with $1,000 per month for three years. Applicants must meet all of the following requirements: Be 18 years of age or older Live in a Los Angeles County neighborhood that falls at or below 100% of the County’s Area Median Household Income (AMI)…...... Read More

March 3, 2022

The LEAD program was developed to support early-career investigators from racial/ethnic minority groups that are traditionally underrepresented in the substance use disorder research field. This program is integrated within the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) and serves as a platform for training early career research scientists. Based at the University of California, San Francisco (UCSF), this 3-year training program utilizes a team mentoring approach. Visiting scholars spend three summers in…...... Read More

February 2, 2022

CBAM’s mobile clinic team continues its conduct of the INTEGRA study bringing treatment for opioid use disorder, as well as HIV prevention and treatment, directly to those who need it. This past week, we were at the LA Grand Hotel. The Hotel is currently a Project Room Key site, a collaborative effort by the State, County and the Los Angeles Homeless Services Authority to secure hotel and motel rooms for vulnerable people experiencing homelessness. It…...... Read More

January 25, 2022

Methamphetamine (MA) related overdose deaths have increased dramatically in the United States in the past several years. MA use is linked to a variety of adverse health related conditions and can complicate the management of chronic and infectious disease and severely impact one’s overall quality of life. There are currently no FDA approved medications for the treatment of Methamphetamine Use Disorder and there are a limited number of effective behavioral treatment options. Researchers at UCLA,…...... Read More

December 27, 2021

The UCLA Vine Street Clinic served as one of the study sites for the HPTN 083 trial, a study that sought to compare the efficacy of cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention. Data obtained from this and other studies helped inform the U.S. Food and Drug Administration (FDA)’s approval of long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. “Results of this NIAD/NIH sponsored and co-funded study showed that CAB-LA…...... Read More

December 7, 2021

“A study of HIV-positive black and Latino men who have sex with men finds the use of methamphetamine combined with intimate partner violence boosted the activity of genes that regulate the body’s inflammatory and antiviral functions.” Researchers of this study-including CBAM’s own Drs. Michael Li, Mariah Kalmin & Steven Shoptaw, sought to further understand the link between stress biology and substance use disorders as these findings demonstrate that both social challenges and substance use play…...... Read More

November 18, 2021

The University of New South Wales Sydney (UNSW) & National Drug and Alcohol Research Centre (NDARC) recently invited Dr. Steven Shoptaw to lecture at a collaborative seminar titled, ASCEND: Therapeutic Interventions for Methamphetamine Dependence. Methamphetamine dependence is a growing public health concern in Australia and many parts of the world. There are currently no approved pharmacotherapies for its treatment, but researchers have been evaluating potentially effective medications as possible treatment options. The ASCEND program (Advancing…...... Read More

November 3, 2021

Dr. Shoptaw was given the honor to present a talk, ‘Medications as Foundation for Stimulant Use Disorder Treatment: Is it Time?’, at this year’s annual Eric D. Hadar Distinguished Lecture at the Columbia University Department of Psychiatry. Since its inception in 2016, the Eric D. Hadar Distinguished Lecture series has broadened the discussion and understanding of current research findings related to substance use disorders and their available treatment options. Columbia’s Division of Substance Use Disorders…...... Read More

March 1, 2021

Q2i is a digital health company that develops technology designed to improve treatment for Substance Use Disorder (SUD). OARS technology is utilized by Medication-Assisted Treatment (MAT) program providers, an approach that combines medication (i.e. methadone and buprenorphine) with counseling and behavioral therapies to reduce and treat Opioid Use Disorder (OUD). The application developed by Q2i features a healthcare team portal along with a patient mobile application that allows providers to examine real time reporting and…...... Read More

February 16, 2021

As you may have read in our annual report, CBAM is preparing to go mobile! We are procuring a mobile clinic equipped with two rooms that will allow us to bring addiction treatment and HIV prevention directly to those most in danger of opioid overdose. This new research project is led by our own Dr. Shoptaw and coordinated through the HIV Prevention Trials Network with collaborating sites in Houston, Pittsburgh, Washington DC, and the Bronx.…...... Read More

February 11, 2021

Dr. Madhukar Trivedi recently presented the paper featured on The New England Journal of Medicine titled “Naltrexone plus Bupropion in Methamphetamine Use Disorder” during the Biweekly CTN Big South/West Node Journal Club. The Journal Club promotes an educational environment where colleagues can discuss and evaluate academic literature and identify new research methods or findings in their respective fields. To view the 1/27/21 Journal Club session click here....... Read More

January 22, 2021

Dr. Shoptaw recently co-authored a paper in The New England Journal of Medicine, titled “Naltrexone plus Bupropion in Methamphetamine Use Disorder.” Currently, there is no medication approved by the Food and Drug Administration (FDA) for the treatment of methamphetamine use disorder. In the paper, Dr. Shoptaw and co-authors discuss a clinical trial that examined two drugs-Naltrexone and Bupropion-used in combination to help those with methamphetamine use disorder avoid relapse. Bupropion is a stimulant like anti-depressant…...... Read More

January 7, 2021

2021 NIDA Summer Research Internship Program Call for Applications- Application Deadline: February 12, 2021. Substance abuse and addiction research internship opportunity: The NIDA Summer Research Internship Program introduces undergraduate students, with a goal of increasing underrepresented groups in biomedical and behavioral sciences, to substance abuse and addiction research. Through this program, undergraduate students age 18 years and older, conduct substance abuse and addiction research by participating in internships with NIDA funded scientists at universities across…...... Read More

November 16, 2020

Interim Analysis Shows High Efficacy Rate for the mRNA-1273 Vaccine It was announced today that the Moderna COVID-19 vaccine trial “has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.” This is based on the first interim analysis of the data, conducted by an independent, NIH-appointed Data Safety Monitoring Board. Of the 30,000 participants enrolled in the trail, one half received the vaccine and one half received…...... Read More

August 25, 2020

The UCLA Vine Street Clinic has begun enrollment in the Moderna trial. This is one of several studies seeking a vaccine for SARS-CoV-2, also known as COVID-19. The purpose of this study is to test Moderna’s vaccine candidate (mRNA-1273) to see if it can prevent illness in people who are exposed to the SARS-CoV-2 virus in their everyday lives. This vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid…...... Read More

July 23, 2020

The National Institute on Drug Abuse (NIDA) has awarded a 5-year, $7.5million grant to fund the Big South/West Node of the Clinical Trials Network (CTN). Steven Shoptaw, PhD, Director of the Center for Behavioral & Addiction Medicine and Professor and Vice Chair of Research for the UCLA Department of Family Medicine, will share leadership of the node with Madhukar H. Trivedi, MD, Director of the Center for Depression Research and Clinical Care and Professor of…...... Read More

June 28, 2020

  On April 30, Dr. Keith Heinzerling was quoted in an article about rising alcohol sales during the pandemic. The isolation and stress caused by stay-at-home orders and the easy availability of alcohol through home delivery services has made it increasingly difficult for people in recovery to maintain their sobriety. However, Dr. Heinzerling noted that “Avoiding alcohol and drug use will help to keep you and your immune system as healthy as possible to avoid…...... Read More

June 28, 2020

On April 16, CBAM’s Dr. Steve Shoptaw and colleagues published a Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19 in the journal AIDS and Behavior. Their goal: to ensure that our response to the COVID-19 crisis does not erode the significant gains made in HIV treatment and prevention. We must find ways to address COVD-19, to ensure the health and safety of our staff and our patients, while also…...... Read More

June 28, 2020

On April 15, our paper “Trajectories of viral suppression in people living with HIV receiving coordinated care: Differences by comorbidities” was highlighted in the New England Journal of Medicine’s (NEJM) Journal Watch, where NEJM physician editors select and summarize important research, medical news, drug information, public health alerts and clinical guidelines across 12 specialties. The paper, led by Dr. Michael Li, assessed obstacles to improved HIV-cascade care for patients enrolled in the LA County Public…...... Read More

February 20, 2020

CBS reported on their February, 19, eleven o’clock nightly news broadcast that three student deaths at USC which occurred this past Fall were recently found to be the result of accidental overdoses of fentanyl. Click here to watch the full 4-minute segment including an interview with CBAM Executive Director, Dr. Steven Shoptaw....... Read More

November 5, 2019

Our very own Dr. Shoptaw recently co-authored a paper in the Lancet’s Series on Drug Use, titled “Responding to global stimulant use: challenges and opportunities.” In the paper, Dr. Shoptaw and co-authors discuss the rising problem of stimulant use, with an emphasis on amphetamine and cocaine use. The increase in use of this class of drugs requires specific, tailored responses to reduce the harm they bring to communities, both fatal and non-fatal, such as poor…...... Read More

September 16, 2019

The goal of the study was to learn about the experiences of PrEP-related stigma among Black and Latina transgender women (TW) who are using PrEP in Los Angeles County. Our findings revealed that participants experience HIV stigma directly related to their identity as TW, due to the high prevalence in the population. This context helped us to better understand the experiences of stigma related to their PrEP use. The three themes surrounding PrEP stigma included:…...... Read More

August 26, 2019

The UCLA Vine Street Clinic in partnership with the UCLA CARE Center attended the 4th Annual DTLA Proud Festival. Research participants from both centers were given free admission tickets to this year’s event, as a token of our appreciation for their efforts and contribution to research....... Read More

January 30, 2019

UCLA Addiction Medicine Fellowship is Accepting Applications! The UCLA Department of Family Medicine is currently accepting applications for its one-year clinical fellowship in Addiction Medicine. The overall educational goals for the fellowship program will be obtained through longitudinal continuity of care experiences, clinical core rotations, program specific rotations, elective rotations and scholarly activities. For more information or to download the application, visit https://www.uclahealth.org/family-medicine/addiction-medicine....... Read More

January 7, 2019

2019 NIDA Summer Research Internship Program Call for Applications- Application Deadline: February 11, 2019. Substance abuse and addiction research internship opportunity: The NIDA Summer Research Internship Program introduces undergraduate students, with a goal of increasing underrepresented groups in biomedical and behavioral sciences, to substance abuse and addiction research. Through this program, undergraduate students age 18 years and older, conduct substance abuse and addiction research by participating in internships with NIDA funded scientists at universities across…...... Read More

December 20, 2018

CBAM has been working for decades on issues surrounding substance use and HIV. Through our research, we seek to better understand the impact of substance use on HIV transmission and progression and on general health. In a recent study published in the journal Drug and Alcohol Dependence, our researchers compared gay and bisexual men with methamphetamine dependence to matched controls and found that death rates were three times higher in methamphetamine-dependent individuals than in the…...... Read More

December 19, 2018

You are cordially invited to the University of Southern California’s Institute for Addiction Science’s Speaker Series talk by Dr. Stephen T. Higgins, titled “Changing Drug Use and Other Health-related Behavior in Vulnerable Populations.” Stephen T. Higgins, Ph.D., is Director of the University of Vermont’s (UVM) Vermont Center on Behavior and Health (VCBH). The Center is supported by multiple federal grants including the Centers of Biomedical Research Excellence (COBRE) Award from NIGMS, and the Tobacco Centers…...... Read More

December 12, 2018

Last month, Dr. Shoptaw had the distinct pleasure of moderating a Los Angeles World Affairs Council Book Event. The event, which took place on November 28 in Culver City, allowed for an energetic discussion regarding the opioid epidemic.   From the LAWAC website: “Last year, thousands of Americans died from overdosing on prescription painkillers. The issue, says Guardian journalist and author Chris McGreal, is not just misuse, but over-prescription by doctors and a lack of…...... Read More

November 27, 2018

Today is #GivingTuesday, a global day of giving that kicks off the charitable season. This year, consider making a donation to CBAM. The latest figures from the National Survey on Drug Use and Health indicate what we at CBAM have been seeing for some time – that there are major gaps in treatment for substance users and our most vulnerable continue to be left out. The same is true for HIV prevention and care. CBAM…...... Read More

October 10, 2018

Nic Sheff, author of “Tweak” and David Sheff, author of “Beautiful Boy” were joined Dr. Steven Shoptaw and Dr. Larissa Mooney of UCLA as part of the Friends of Semel screening of the upcoming film “Beautiful Boy” based on the family’s struggle with and recovery from addiction. The movie stars Steve Carell as David and Timothee Chalamet as Nic. After the film, the panel discussed issues of addiction.   Photos courtesy of Reed Hutchingson Photography....... Read More

August 16, 2018

In September 2017, the Drug Policy Alliance organized a conference in Los Angeles in partnership with over a dozen organizations, including the Center for Behavioral and Addiction Medicine (CBAM), titled “Stimulant Use: Harm Reduction, Treatment, and Future Directions.” The conference aimed to bring attention to a large class of drugs that has received inconsistent attention from the media, harm reduction and treatment communities, researchers, and policymakers alike. Los Angeles was chosen for this conference due…...... Read More

August 1, 2018

We’re so excited to see the positive results of this program to assist federally qualified community health centers in the implementation of medication-assisted treatment (MAT) for opioid addiction. CBAM’s Dr. Keith Heinzerling was one of several MAT experts engaged by the program to provide direct coaching assistance to participating health centers. Program highlights include a shift in perspective about addiction and the use of MAT, as well as an increase in the number of patients…...... Read More

April 6, 2018

A word from Dr. Steven Shoptaw: One of the world pioneers in HIV medicine in India was not only a physician scientist and inspiring human being, but apparently also a matchmaker! What is even better, is that Suniti continues to impact our world today when you look at this film trailer: lovesickthefilm.com Those of you privileged to have met Suniti Solomon will experience the same shock and thrill when you see her standing there, in…...... Read More

March 9, 2018

Dr. Shoptaw traveled back to Cape Town, South Africa in February! While there, he met with our team at the University of Cape Town as they finish up a research project looking at the neuroscience behind contingency management for methamphetamine users. He also met with additional faculty at the University of Cape Town to discuss several exciting new research endeavors to expand our global efforts. We aim to bring the innovative, state-of-the-art interventions to Cape…...... Read More

About

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities. As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

© The UCLA Center for Behavioral & Addiction Medicine (CBAM). All Rights Reserved.